Refine by
Influenza Virus Articles & Analysis
27 news found
Influenza A virus is a genus of virus in the family Orthomyxoviridae and causes influenza in birds and some mammals. Influenza A virus strains of all subtypes have been isolated from wild birds, but disease is rare. ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. ...
Infectious Diseases: Antibodies are developed against rapidly evolving pathogens, such as the influenza virus and SARS-CoV-2. In addition to Antibody De Novo Design, CD ComputaBio's platform extends its capabilities to Protein Drug Design, enabling the creation of highly efficient and specific small molecule drugs. ...
Meanwhile, it is critical to keep the virus concentration low so as to detect infection and not saturate antibodies in the serum. ...
In addition, these new reagents can be applied in various fields, such as mRNA-base vaccine therapy for malignant tumors, protein replacement therapy, and gene editing using mRNA recombination technology. mRNA vaccines protect against infectious diseases like influenza, rabies, HIV and Zika virus infections. This mRNA Transfection Reagent (Catalog: WHM-OB24, unit ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. ...
Neuraminidase (NA), also known as sialidase, is a glycoprotein distributed on the envelope of the influenza virus. It is antigenic and can catalyze the hydrolysis of sialic acids, helping mature influenza viruses detach from host cells and infect new cells. ...
David and his lab have specialized in research on influenza viruses for several years, they obtain very fruitful findings to be shared in the webinar. ...
The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections and diseases caused by six common devastating viruses – adenovirus (AdV), BK ...
ByKalaris
Many RNA viruses need to activate this pathway to ensure their replication, such as influenza viruses[xii], hantaviruses[xiii], or the respiratory syncytial virus (RSV)[xiii] , and also coronaviruses[xiii] , including SARS-CoV-2. Zapnometinib inhibits the cellular MEK (MAPK/ERK kinase), blocking the formation of functional virus particles in the ...
This study is the second Phase 3 registrational study of posoleucel, following the initiation of the Phase 3 study for the treatment of virus-associated HC last year. Separately, the company also announced the initiation of a Phase 1/2 clinical trial (NCT04933968) of ALVR106, its investigational, allogeneic, off-the-shelf, multi-VST therapy for the treatment of infections caused ...
ByKalaris
This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the Needle collaboration earlier this year, under which the company successfully developed a number of solid-dose formulations of a recombinant H7N9 pandemic influenza vaccine. Under NIAID’s suite of preclinical services, NIAID-funded ...
Martinez-Sobrido, PhD, professor in the Department Disease Intervention & Prevention at Texas Biomed is widely recognized in the development of recombinant viruses, specifically influenza, arenaviruses, and Zika virus, using plasmid-based reverse genetic approaches. ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global Influenza Strategy (2019–2030) report. The unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on ...
Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech's patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics. ...
Thermo Fisher Scientific announces CE-marking of its TaqPath COVID-19, Flu A/B, RSV Combo Kit for the in vitro diagnosis of SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV) A/B infections. Using the new kit, laboratories can now can run a single test for SARS-CoV-2, influenza (flu) A/B, and RSV to detect and differentiate between ...
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or ...
Hence, polyclonal antibodies are better adapted to potential changes the antigen may undergo, e.g., after a virus mutation. Using an antigen derived from SARS-CoV-2, the company has launched a development programme for polyclonal antibodies F(ab’)2 to be administered by injection to hospital inpatients, in order to generate passive immunity in these patients. These ...
SaNOtize also announced that new tests conducted by the Institute for Antiviral Research at Utah State University confirm SaNOtize’s Nitric Oxide Releasing Solution (NORSTM) inactivated more than 99.9% of SARs-CoV-2, the virus that causes COVID-19, within two minutes, in laboratory tests. ...